CALC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CalciMedica Inc (CALC) is not a strong buy at this time for a beginner investor with a long-term focus. The stock faces significant challenges, including a recent clinical trial discontinuation, weak financials, and limited positive catalysts. While there is some potential upside in the long term, the risks outweigh the rewards for this investor profile.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 0.663, suggesting limited immediate upside.
Oppenheimer views the stock as oversold and sees potential in Auxora's $200M opportunity in acute pancreatitis (AP).
The discontinuation of the Phase 2 KOURAGE clinical trial removes a major growth catalyst. Liquidity concerns persist, with only $13M in cash and short-term investments. Analysts have downgraded the stock, and there is no clear path forward for growth.
The company reported a FY GAAP EPS of -$1.97, reflecting significant profitability challenges. Q3 2025 financials show no revenue, a net income loss of $7.8M (though improved YoY), and an EPS of -0.52. The company has limited cash reserves, expected to last until Q4 2026.
H.C. Wainwright downgraded the stock to Neutral due to the clinical trial discontinuation. Oppenheimer maintains an Outperform rating but acknowledges significant risks.
